Schilder R J, Boente M P, Corn B W, Lanciano R M, Young R C, Ozols R F
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Oncology (Williston Park). 1995 Feb;9(2):171-82; discussion 185-7.
Approximately one third of patients with epithelial ovarian cancer present with localized or early-stage disease. Prognostic features identify certain subsets of patients with good risk characteristics who do not require adjuvant treatment after comprehensive surgical staging and cytoreduction. Only a minority of patients undergo such a complete procedure, which often results in understaging of these patients. In the United States, patients with poor prognostic features, such as stage IC to II disease, poorly differentiated histologic grade, clear cell histology, dense adhesions, and large volume ascites, have received adjuvant chemotherapy. Single-agent or combination chemotherapy, whole abdominal irradiation, and intraperitoneal phosphorus 32 have been evaluated, although no modality has been shown to improve overall survival. Randomized trials investigating the optimal therapy or whether any therapy is truly effective are in progress. Until the completion of these trials, the most common postoperative adjuvant therapy in these patients in this country remains combination chemotherapy.
大约三分之一的上皮性卵巢癌患者表现为局限性或早期疾病。预后特征可识别出某些具有良好风险特征的患者亚组，这些患者在进行全面的手术分期和肿瘤细胞减灭术后不需要辅助治疗。只有少数患者接受这样的完整手术，这往往导致这些患者分期不足。在美国，具有不良预后特征的患者，如IC期至II期疾病、组织学分级差、透明细胞组织学、致密粘连和大量腹水，已接受辅助化疗。单药或联合化疗、全腹照射和腹腔内磷32已被评估，尽管没有一种治疗方式被证明能提高总生存率。正在进行研究最佳治疗方法或任何治疗是否真的有效的随机试验。在这些试验完成之前，该国这些患者最常见的术后辅助治疗仍然是联合化疗。
